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Persistent pulmonary hypertension (PPH) is a clinical
syndrome, characterized by a sustained elevation of the
pulmonary vascular resistance with a right-to-left shunt ac-
ross the ductus arteriosus and/or the foramen ovale, caus-
ing severe hypoxaemia. Although generally associated with
diseases of term newborns PPH has been increasingly de-
scribed in preterm infants as well [1]. Inhaled nitric oxide
(iNO) has been described as an effective selective pulmo-
nary vasodilator improving oxygenation in newborns inclu-
ding preterm infants. However, concern over iNO relates
to its potential toxicity and to difficulties in developing
safe and effective delivery systems. Intravenous prostacy-
clin (epoprostenol) is a potent vasodilator in PPH [2].
Nevertheless, its effect on systemic vasculature and on
pulmonary vessels of nonventilated areas limits its clinical
application. Recently, aerosolized prostacyclin has been
reported both in clinical and experimental settings to be a
selective pulmonary vasodilator without side-effects on
the systemic vasculature [3–5]. No human data on topical
epoprostenol-related toxicity are available. In an animal
study no signs of acute pulmonary toxicity were shown
from prostacyclin inhalation [6]. We here describe the
effect of endotracheal instillation of prostacyclin on oxy-
genation and haemodynamics in four preterm infants with
severe pulmonary hypertension.
Patients and methods 
The patients' underlying diseases were hyaline mem-
brane disease (patients 1–3) and septicaemia caused by
Escherichia coli (patient 4). Demographic data are listed in
table 1. All patients had an arterial oxygen tension (Pa,O2)/
fraction of inspired oxygen (FI,O2) ratio <70 despite opti-
mum ventilator settings during at least 6 h. Oxygenation
was monitored using pre- and postductal transcutaneous
pulse oximetry and a pre- and/or postductal indwelling
arterial catheter. The variables measured and calculated
were the Pa,O2/FI,O2, the oxygenation index (OI; ((FI,O2 ×
mean airway pressure)/ Pa,O2) × 100) and mean systemic
arterial blood pressure (MAP). Patients were only enrolled
after informed consent was obtained from the parents. In
all infants the presumptive diagnosis of persistent pulmo-
nary hypertension was confirmed with air-contrast echo-
cardiography showing a right-to-left shunt across the ductus
arteriosus and/or the foramen ovale. The epoprostenol, dis-
solved in glycine buffer (Flolan®, GlaxoWellcome B.V.,
Zeist, the Netherlands), was diluted with saline (NaCl 0.9%)
to a concentration of 50 ng·mL-1. The pH of this solution
was 10.3. This epoprostenol solution of 50 ng·mL-1 was
instilled as a bolus of 1 mL·kg-1 endotracheally through a
catheter reaching the distal end of the endotracheal tube.
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ABSTRACT: Does endotracheal instilled prostacyclin (epoprostenol) improve oxy-
genation in preterm infants with persistent pulmonary hypertension?
Four preterm infants were studied. Prostacyclin  (50 ng·kg-1) was injected as an
endotracheal bolus. In two patients the prostacyclin bolus was repeated and in one
patient prostacyclin was administered continuously. Oxygenation was evaluated thro-
ugh the oxygenation index and the ratio of arterial oxygen tension to the fraction of
inspired oxygen. The mean arterial blood pressure was used to evaluate systemic cir-
culation. 
The oxygenation index (±SD) decreased significantly from 39 (±13.3) to 7 (±2.5) and
the ratio of arterial oxygen tension to the fraction of inspired oxygen (±SD) increased
significantly from 47 (±13) to 218 (±67), most likely related to a reduction of the pul-
monary vascular resistance with a reversal of the extrapulmonary shunting at the
ductus arteriosus and atrial level. The blood pressure did not change. All effects were
reversed on drug withdrawal. Repeated or continuous endotracheal administration
of prostacyclin in three children demonstrated a sustained response without tachyph-
ylaxis, and without overt side-effects. 
Endotracheal instillation of prostacyclin resulted in an improved oxygenation
without systemic vascular repercussions in four preterm infants with persistent pul-
monary hypertension. Repeated or continuous administration showed a sustained re-
sponse and no overt side-effects were noticed.
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Epoprostenol was administered within 1–2 h after extra-
pulmonal shunting was established with echocardiogram.
In two children the endotracheal instillation of prostacyc-
lin was repeated three times. In a third child, continuous
endotracheal administration of 1 mL·kg-1·h-1 epoprostenol
solution was given for a period of 12 h. Registration of
ventilator settings, blood gases and circulatory parameters
was carried out just before, 10 min after, and at 30 min
intervals after administration of prostacyclin.
Results 
We studied the effects of endotracheal instilled prosta-
cyclin in four infants with persistent pulmonary hyperten-
sion. The administration of 50 ng·kg-1 prostacyclin as an
endotracheal bolus injection decreased the oxygenation
index (±SD) from 39 (±13.3) to 7 (±2.5) (fig. 1b) and in-
creased the ratio of Pa,O2 to FI,O2 from 47 (±13.0) to 218(±66.6) (fig. 1a). Improvement of oxygenation is most
likely related to the reduction of the pulmonary vascular
resistance and reversal of the extrapulmonary shunting
at the ductal and atrial level. The mean systemic arterial
blood pressure did not change after prostacyclin instil-
lation (fig. 1c). The endotracheal instillation procedure
was well tolerated and no adverse cardiocirculatory events
occurred. Effects on oxygenation were reversed on drug
withdrawal. Repeated or continuous endotracheal admin-
istration of prostacyclin in three infants demonstrated a
sustained response without tachyphylaxis and without overt
side-effects.
Discussion 
PPH in term and preterm infants is a complex disorder
characterized by an altered vasoreactivity with a marked
pulmonary hypertension leading to a right-to-left shunting
of blood across the patent ductus arteriosus and foramen
ovale. Mechanisms for the vascular tone dysregulation are
incompletely understood. However, a dysbalance of endo-
genous vasodilators (such as prostacyclin or endothelium-
derived NO) and vasoconstrictors (such as thromboxane
A2) play a role in this process [7]. In recent years iNO has
been shown to improve oxygenation through a selective
pulmonary vasodilation without repercussion on the sys-
temic vasculature. Two recent prospective controlled trials
demonstrated a reduced incidence of the invasive extracor-
poreal membrane oxygenation therapy in term newborns
suffering PPH, however, without improvement of morbid-
ity and mortality rates [8, 9]. Although major concern
exists regarding potential toxicities of NO and its metabo-
lites, no evidence of immediate toxic effect was found in
these studies. PELIOWSKI et al. [10] demonstrated an im-prove-
ment in oxygenation with inhaled nitric oxide in eight pre-
term infants. For the preterm infant different
considerations and concerns exist regarding toxicity of
NO and its metabolites [11]. Until now no data of pro-
spective controlled trials in this population have been
available. Important considerations compared with term
newborns are maturational differences in haemoglobin,
coagulation, free radical scavenging systems and sur-
factant metabolism.
Another difficulty in general with iNO is related to a safe
and reliable delivery system [12, 13]. Intravenous prosta-
cyclin is a potent, dose-dependent vasodilator. However,
vasodilation is nonselective, resulting in both systemic
hypotension and an increase of ventilation/perfusion mis-
match in nonventilated areas. Thus, intravenous prostacy-
clin and inhaled NO are potent pulmonary vasodilators,
but each with limitations in clinical application. There-
Table 1.  –  Patient characteristics
Patient
No.
Gestational age
weeks
Birth weight
g Disease
1
2
3
4
30.9
27.1
26.7
33.7
845
745
895
2300
HMD
HMD
HMD
E. coli sepsis
HMD: hyaline membrane disease; E. coli: Escherichia coli.
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Fig. 1.  –  a) the arterial oxygen tension (Pa,O2)/inspiratory oxygen frac-
tion (FI,O2) ratio, b) the oxygenation index and c) the mean arterial
blood pressure are all shown before and after endotracheal instillation
of a bolus of 50 ng·kg-1 epoprostenol. Data are presented as mean and
SD.
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fore, WALMRATH et al. [4] studied the effect of prostacyclin
aerosol (17–50 ng·kg-1·min-1) on the lung vasculature in
humans. They showed pulmonary vasodilation in three
adults with acute respiratory distress syndrome, together
with reduced shunt-flow and improved arterial oxygena-
tion, suggesting that the endotracheal route of prostacyclin
ap-plication probably allows targeting of prostanoid activ-
ity to lung vessels in well-ventilated areas. BINDL et al. [3]
and ZWISSLER et al. [14] investigated the effect of endotra-
cheal prostacyclin in three term newborns with PPH [2]
and congenital heart disease [1], respectively. They also
found an improvement in oxygenation without repercus-
sions on the systemic circulation. 
Our data indicate that, in preterm infants who suffer
from hyaline membrane disease or sepsis with persistent
pulmonary hypertension, endotracheal instillation of 50
ng·kg-1 prostacyclin resulted in a significant improvement
of arterial oxygenation by reversal of the extrapulmonal
shunting. Repeated endotracheal instillation of 50 ng·kg-1
prostacyclin showed sustained responses. Even continu-
ous administration of 50 ng·kg-1·h-1 during 12 consecutive
hours demonstrated a sustained response without any
sign of tachyphylaxis. No negative systemic vascular effects
were noticed with this dosage. It is not known whether
a higher dosage would result in systemic effects due to
resorption of the epoprostenol. For stability reasons epo-
prostenol is prepared in a glycine buffer (pH 10.5). There-
fore, concerns can be raised regarding topical application
of a highly alkaline solution within the airways of preterm
infants. An animal study showed no acute toxicity of
endotracheal administered prostacyclin in healthy lambs
[6]. However, no data exist on the toxicity of topical epo-
prostenol in preterm infants and further randomized studies
should be performed to investigate differences in toxicities
at different strategies using prostacyclin therapy. ZOBEL et al.
[5] compared inhaled nitric oxide and inhaled prostacyclin
as selective pulmonary vasodilators in piglets. They dem-
onstrated an improvement in oxygenation mainly due to
improved mismatch of pulmonary perfusion and ven-tila-
tion. In contrast to NO, measurement of the inspired con-
centration is unnecessary. However, concern exists re-
garding the deposition of aerolized or instilled medica-
tion. The exact dose and mode of administration has to be
investigated in further studies. The use of surfactant as a
potential carrier of prostacyclin might prove to be a useful
alternative in the treatment of pulmonary hypertension in
preterm newborns with hyaline membrane disease and
pulmonary hypertension.
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